2. Academic Validation
  3. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells

iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells

  • Nanomedicine (Lond). 2015;10(17):2677-95. doi: 10.2217/nnm.15.106.
Xiaoli Mao 1 2,  Junjie Liu 1,  Zhirong Gong 1,  He Zhang 1,  Ying Lu 1 2,  Hao Zou 1,  Yuan Yu 1,  Yan Chen 1,  Zhiguo Sun 1,  Wei Li 3,  Bohua Li 3,  Jie Gao 1,  Yanqiang Zhong 1 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China.
  • 2 School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian, China.
  • 3 International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
PMID: 26355733 DOI: 10.2217/nnm.15.106
Abstract

Aims: To develop novel iRGD (internalizing Arg-Gly-Asp peptide)-conjugated DSPE-PEG2000 nanomicelles (M-SAL-iRGD) for delivery of salinomycin to both liver Cancer cells and Cancer Stem Cells (CSCs).

Materials & methods: The characterization, antitumor activity and mechanism of action of M-SAL-iRGD were evaluated.

Results & conclusion: M-SAL-iRGD possessed a small size of around 10 nm, and drug encapsulation efficacy higher than 90%. M-SAL-iRGD showed significantly increased cytotoxic effect toward both nontargeted M-SAL (salinomycin-loaded DSPE-PEG2000 nanomicelles) and salinomycin in both liver Cancer cells and CSCs. The tissue distribution and antitumor assays in mice bearing liver Cancer xenograft confirmed the superior penetration tumor efficacy and antitumor activity of M-SAL-iRGD. M-SAL-iRGD represent a potential effective nanomedicine against liver Cancer.

Keywords

cancer nanotechnology; cancer stem cells; iRGD; liver cancer; micelles.

Figures
Products